UK biotech Synairgen is pushing ahead with a phase 3 trial of SNG001 in hospitalised COVID-19 patients, after encouraging topline results from a phase 2 study that started last March.

An inhaled drug developed by the UK firm Synairgen greatly reduces the chances of patients hospitalised with COVID-19 from progressing to more serious stages of the disease. Southampton ...

London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves ...

As of 10:56 BST. Market open. There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com ...

As of 8:01 am GMT+2. Market open. There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com ...

This page features the latest Synairgen share stories and breaking news. Assess the latest information about the Synairgen stock. Our team of expert financial journalists are ready to bring you ...

Here's a reminder of the day he first suggested bleach injections and UV light - inside the body :) The most recent information from Synairgen suggests that the trial finance is in place ...